Abstract
Nanocarriers can penetrate the tumour vasculature through its leaky endothelium and, in this way, accumulate in several solid tumours. This is called the enhanced permeation and retention (EPR) effect. Together with nanocarriers whose surface is tailored for prolonged blood circulation times, the concept is referred to as passive targeting. Targeting ligands, which bind to specific receptors on the tumour cells and endothelium, can be attached on the nanocarrier surface. This active targeting increases the selectivity of the delivery of drugs. Passive and active drug targeting with nanocarriers to tumours reduce toxic side-effects, increase efficacy, and enhance delivery of poorly soluble or sensitive therapeutic molecules. In this review, currently studied and used passive and active targeting strategies in cancer therapy are presented
Keywords: Active targeting, cancer therapy, nanocarriers, passive targeting, stealth, inflammation, nucleic acid, Tumour vasculature, epithelium, endothelium
Current Drug Discovery Technologies
Title: Passive and Active Tumour Targeting with Nanocarriers
Volume: 8 Issue: 3
Author(s): Samuli Hirsjarvi, Catherine Passirani and Jean-Pierre Benoit
Affiliation:
Keywords: Active targeting, cancer therapy, nanocarriers, passive targeting, stealth, inflammation, nucleic acid, Tumour vasculature, epithelium, endothelium
Abstract: Nanocarriers can penetrate the tumour vasculature through its leaky endothelium and, in this way, accumulate in several solid tumours. This is called the enhanced permeation and retention (EPR) effect. Together with nanocarriers whose surface is tailored for prolonged blood circulation times, the concept is referred to as passive targeting. Targeting ligands, which bind to specific receptors on the tumour cells and endothelium, can be attached on the nanocarrier surface. This active targeting increases the selectivity of the delivery of drugs. Passive and active drug targeting with nanocarriers to tumours reduce toxic side-effects, increase efficacy, and enhance delivery of poorly soluble or sensitive therapeutic molecules. In this review, currently studied and used passive and active targeting strategies in cancer therapy are presented
Export Options
About this article
Cite this article as:
Hirsjarvi Samuli, Passirani Catherine and Benoit Jean-Pierre, Passive and Active Tumour Targeting with Nanocarriers, Current Drug Discovery Technologies 2011; 8 (3) . https://dx.doi.org/10.2174/157016311796798991
DOI https://dx.doi.org/10.2174/157016311796798991 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
LRRC4 Inhibits Glioma Cell Growth and Invasion Through a miR-185- Dependent Pathway
Current Cancer Drug Targets Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry Brain Tumor Segmentation Using Deep Belief Networks and Pathological Knowledge
CNS & Neurological Disorders - Drug Targets Recent Advances of Aminopyrimidines in Multicomponent Reactions
Current Organic Chemistry Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Anticancer Mechanisms of Bioactive Peptides
Protein & Peptide Letters Quasi-Life Self-Organizing Systems: Based on Ensembles of Succinylated Derivatives of Interferon-Gamma
Current Medicinal Chemistry Molecular Mechanisms Regulating mRNA Stability: Physiological and Pathological Significance
Current Genomics Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Adhesion Mechanisms of the Lyme Disease Spirochete, Borrelia burgdorferi
Current Drug Targets - Infectious Disorders Biocatalytic Synthesis of Terpene Esters and their Biological Activity in Human Glioma Cells
Current Pharmaceutical Biotechnology Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Lipoidal-Nano Architecture for Parental Drug Delivery: Formulation Development and Regulatory Concerns
Current Applied Polymer Science Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention
MicroRNA Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Targeting the AKT Pathway in Glioblastoma
Current Pharmaceutical Design The Recent Medicinal Chemistry Development of Jak2 Tyrosine Kinase Small Molecule Inhibitors
Current Medicinal Chemistry Patents in Cancer Stem Cells
Recent Patents on Biomarkers